Attached files
| file | filename |
|---|---|
| EX-10.29 - CONSULTING AGREEMENT - Immune Therapeutics, Inc. | tnib_ex1029.htm |
| EX-10.21 - PROMISSORY NOTE SETTLEMENT AGREEMENT - Immune Therapeutics, Inc. | tnib_ex1021.htm |
| EX-32.1 - CERTIFICATE - Immune Therapeutics, Inc. | tnib_ex321.htm |
| EX-31.1 - CERTIFICATE - Immune Therapeutics, Inc. | tnib_ex311.htm |
| EX-21.1 - LIST OF SUBSIDIARIES - Immune Therapeutics, Inc. | tnib_ex211.htm |
| EX-31.2 - CERTIFICATE - Immune Therapeutics, Inc. | tnib_ex312.htm |
| EX-10.20 - PROMISSORY NOTE SETTLEMENT AGREEMENT - Immune Therapeutics, Inc. | tnib_ex1020.htm |
| EX-10.28 - SERVICES AGREEMENT - Immune Therapeutics, Inc. | tnib_ex1028.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Immune Therapeutics, Inc. | Financial_Report.xls |
| 10-K - ANNUAL REPORT - Immune Therapeutics, Inc. | tnib_10k.htm |
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Immune Therapeutics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Aronstam, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
Date: March 31, 2015
|
By:
|
/s/ Peter Aronstam
|
|
|
Peter Aronstam
|
|||
|
Chief Financial Officer
|